BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of the current study is to investigate the efficacy, safety and
pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on
therapy to on going metformin therapy in patients with T2DM with insufficient glycemic
control. In addition, there will be an open-label treatment arm with sitagliptin (JanuviaTM)
as add-on therapy to metformin.